Coronation Street confirms character return for Ray Crosby drama amid death fears
Coronation Street baddie Ray Crosby gets a taste of his own medicine next week, when gangster Mick Chaney returns with a warning
Updated
Sign up!
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
Coronation Street spoilers have confirmed a character return for next week - with it not previously known that Ray Crosby knew the person in question.
Gangster Mick Chaney is back, months after threatening to murder Todd Grimshaw - who he revealed to be an ex who conned him out of his money.
If it goes wrong, it could be curtains for him, very literally.
Corrie villain Mick previously appeared in the show late last year as part of Todd Grimshaw s return storyline.
Mick was out to kill Todd after the schemer had stolen money from him, but in a bizarre twist, he ultimately let the matter drop after a telling-off from Eileen.
Coronation Street airs these scenes on Monday, January 18 at 7.30pm and 8.30pm on ITV.
Digital Spy now has a newsletter – sign up to get it sent straight to your inbox.
Avacta Submits Clinical Trial Application for AVA6000 pro-doxorubixin FAP-activated Doxorubicin prodrug
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that it has submitted a Clinical Trial Application (CTA) in the UK for a Phase 1, first-in-human, open label, dose-escalation and expansion study of its lead pre|CISION prodrug, AVA6000, in patients with locally advanced or metastatic selected solid tumours.
In AVA6000, Doxorubicin has been modified with Avacta s pre|CISION chemistry which renders the modified drug inactive in the circulation until it enters the tumour micro-environment where it is activated by an enzyme called FAP (fibroblast activation protein) which is in high abundance in most solid tumours but not in healthy tissue such as the heart. AVA6000 has been shown in animal models to significantly increase the amount of active drug in a tumour